Moderna hosted its Science Day on June 25, 2026, to detail updates to its research and early development pipeline. The company is moving mRNA-6007, a new in vivo CAR-T program, into development for autoimmune diseases such as systemic lupus erythematosus. This expansion marks a new therapeutic modality for the mRNA platform.
In oncology, mRNA-2808 showed encouraging early signals in multiple myeloma. These results support the advancement of mRNA-2151 for the treatment of ovarian cancer.
Moderna is also proceeding with dose escalation for its multiple sclerosis therapeutic, mRNA-1195, in a Phase 2 study. A new cancer prevention study for Lynch syndrome, mRNA-4194, is scheduled to begin this summer.
These developments underscore Moderna's strategy to evolve into a multi-franchise company beyond infectious diseases.